PMID- 23517576
OWN - NLM
STAT- MEDLINE
DCOM- 20130925
LR  - 20220419
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 13
IP  - 5
DP  - 2013 May
TI  - Anti-IgE--emerging opportunities for Omalizumab.
PG  - 765-77
LID - 10.1517/14712598.2013.782391 [doi]
AB  - INTRODUCTION: Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal 
      antibody that selectively binds to free and membrane-bound immunoglobulin E (IgE) 
      antibodies. Omalizumab has been licensed for use in severe allergic asthma. A 
      search on the website clinicaltrials.gov reveals there are currently 109 clinical 
      trials with Omalizumab of which 46 are for conditions other than asthma. AREAS 
      COVERED: In addition to asthma, Omalizumab has been investigated in various other 
      conditions including perennial and seasonal allergic rhinitis (AR), peanut 
      allergy, latex allergy, atopic dermatitis, chronic urticaria (CU), idiopathic 
      anaphylaxis, mastocytosis, eosinophilic gastroenteritis and nasal polyposis. This 
      review aims to look at the various randomised and non-randomised clinical trials, 
      case series and case reports for the role of Omalizumab in conditions other than 
      asthma. Numerous clinical trials have shown a positive light on the role of 
      Omalizumab in conditions other than asthma. EXPERT OPINION: We feel that the 
      future of Omalizumab would include a more diverse range of clinical conditions, 
      and future trials should not only look into the clinical usefulness but also the 
      economic impact of using this interesting molecule.
FAU - Babu, K Suresh
AU  - Babu KS
AD  - Queen Alexandra Hospital, Respiratory Medicine, Level C, Southwick Hill Road, 
      Cosham, Portsmouth, PO6 3LY, UK. sureshbabu97@gmail.com
FAU - Polosa, Riccardo
AU  - Polosa R
FAU - Morjaria, Jaymin B
AU  - Morjaria JB
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130322
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Wasp Venoms)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Asthma/drug therapy
MH  - Dermatitis, Contact/drug therapy
MH  - Food Hypersensitivity/drug therapy
MH  - Gastrointestinal Diseases/drug therapy
MH  - Humans
MH  - Hypersensitivity/*drug therapy
MH  - Immunoglobulin E/*physiology
MH  - Immunotherapy/methods
MH  - Omalizumab
MH  - Rhinitis, Allergic, Perennial/drug therapy
MH  - Rhinitis, Allergic, Seasonal/drug therapy
MH  - Wasp Venoms/immunology
EDAT- 2013/03/23 06:00
MHDA- 2013/09/26 06:00
CRDT- 2013/03/23 06:00
PHST- 2013/03/23 06:00 [entrez]
PHST- 2013/03/23 06:00 [pubmed]
PHST- 2013/09/26 06:00 [medline]
AID - 10.1517/14712598.2013.782391 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2013 May;13(5):765-77. doi: 10.1517/14712598.2013.782391. 
      Epub 2013 Mar 22.